Anti-bacterial Vaccine Compositions
Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
1 - 76 . (canceled)
77 . An attenuated Pasteurellaceae bacterium selected from the group consisting of Pasteurella ( Mannheimia ) haemolytica, Pasteurella multocida , and Actinobacillus pleuropneumoniae comprising a mutation in a polynucleotide sequence that encodes a fhaC polypeptide comprising an amino acid sequence at least 70% identical to the fhaC amino acid sequence of SEQ ID NO: 20, wherein the mutation results in decreased virulence and attenuation of the bacterium.
78 . The bacterium of claim 77 , wherein the mutation results in deletion of all or part of the polynucleotide sequence that encodes the fhaC polypeptide.
79 . The bacterium of claim 77 , wherein the mutation results in an insertion in the polynucleotide sequence that encodes the fhaC polypeptide.
80 . The bacterium of claim 77 that is a Pasteurella multocida bacteria.
81 . An immunogenic composition comprising a bacterium according to claim 77 .
82 . A vaccine composition comprising the immunogenic composition according to claim 81 and a pharmaceutically acceptable carrier.
83 . The vaccine composition according to claim 82 , further comprising an adjuvant.
84 . An attenuated Pasteurellaceae bacterium selected from the group consisting of Pasteurella ( Mannheimia ) haemolytica, Pasteurella multocida , and Actinobacillus pleuropneumoniae comprising a mutation in a polynucleotide sequence that encodes a fhaC polypeptide, wherein the polynucleotide sequence hybridizes to the complement of a polynucleotide sequence set forth in SEQ ID NO: 19 under stringent conditions, such conditions comprising a final wash in buffer comprising 2×SSC/0.1% SDS, at 35° C. to 45° C.
85 . The bacterium of claim 84 , wherein the mutation is in the polynucleotide sequence set forth in SEQ ID NO: 19.
86 . An immunogenic composition comprising the bacterium according to claim 84 or claim 85 .
87 . A vaccine composition comprising the immunogenic composition according to claim 87 and a pharmaceutically acceptable carrier.
88 . The vaccine composition of claim 87 , further comprising an adjuvant.
89 . An attenuated Pasteurella multocida bacterium comprising a mutation in a polynucleotide sequence set forth in SEQ ID NO: 19 that encodes a fhaC polypeptide, wherein the mutation results in decreased virulence and attenuation of the bacterium.
90 . The bacterium of claim 89 , wherein the mutation results in deletion of all or part of the polynucleotide sequence that encodes the fhaC polypeptide.
91 . The bacterium of claim 89 , wherein the mutation results in an insertion in the polynucleotide sequence that encodes the fhaC polypeptide.
92 . An immunogenic composition comprising a bacterium according to claim 89 .
93 . A vaccine composition comprising the immunogenic composition according to claim 92 and a pharmaceutically acceptable carrier.